Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results
Date:5/2/2011

BOSTON, May 2, 2011 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter ended March 31, 2011.

For the three months ended March 31, 2011, PAREXEL’s consolidated service revenue increased by 3.5% to $301.4 million, compared with $291.2 million in the prior year period.  Excluding the positive impact from foreign exchange movements of $3.3 million, revenue increased 2.4%, to $298.1 million.  As reported under Generally Accepted Accounting Principles (GAAP), the Company generated operating income of $21.9 million, or 7.3% of consolidated service revenue, in the third quarter of Fiscal Year 2011, versus GAAP operating income of $25.8 million, or 8.9% of consolidated service revenue, in the comparable quarter of the prior year.   On this basis, GAAP operating income declined 15.3% year-over-year.  The financial results of the March quarter in the current and prior periods each included special items, as detailed in the financial charts within this press release.  Excluding these special items in the current period, adjusted operating income totaled $22.4 million, or 7.4% of consolidated service revenue.  Excluding the special items referenced above in the prior year period, adjusted operating income totaled $29.9 million, or 10.3% of consolidated service revenue.  On this adjusted basis, operating income in the current quarter declined 25.1% year-over-year.  GAAP net income for the current quarter totaled $15.7 million, or $0.26 per diluted share, compared with GAAP net income of $12.8 million, or $0.22 per diluted share, for the quarter ended March 31, 2010.  On a GAAP basis, net income in the current quarter increased by 23.1%, and earnings per diluted share increased by 18.2%.  Adjusted net income in the current period (which excludes the special items
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
2. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
3. PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
5. PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
6. PAREXEL International to Present at Raymond James Investors Conference
7. PAREXEL International to Present at J.P. Morgan Healthcare Conference
8. PAREXEL Opens Clinical Logistics Facilities in Singapore and Russia
9. PAREXEL Wins Clinical Research Team of the Year Scrip Award
10. PAREXEL International to Participate in the Lazard Capital Markets Healthcare Conference in New York and the Jefferies Healthcare Summit in Boston
11. PAREXEL Expert to Lead Track on Global Clinical Outsourcing at Partnerships in Clinical Trials Europe Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Md., March 27, 2007--A new study shows that ... the proportion of,cardiovascular disease (CVD) linked to diabetes ... for increased efforts to,prevent diabetes and to aggressively ... diabetes, according to the investigators,from the long-standing Framingham ...
... the year ended 31 December 2006 , Product ... Phase,III study International partnering process to commerialise M6G,underway ... Pharmaceuticals,plc ("CeNeS" or "the Company"), the CNS focused ... the year ended 31 December 2006. , Operational ...
Cached Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
(Date:7/13/2014)... 14, 2014 Recently, iFitDress.com, one of ... released its beautiful collection of brown evening dresses ... are now available at discounted prices, up to 50% ... of high quality; they are carefully made according to ... occasion gowns, iFitDress.com also offers pretty accessories: wedding shoes, ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Roma vs. Real Madrid Tickets . For the fifth ... International Champions Cup will be held at American stadiums this ... world competing on American soil. The eight teams are split ... the group stage, the top two teams will compete to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Chromatography ... biological components from various types of biological samples ... separate the sample mixture into two phase, namely ... the mobile phase run over the stationary phase, ... the components that provide the separation of mixture. ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4
... ANGELES, March 20 The newest and largest facility ... demolition by the new owner of the Singita Animal ... 210 Freeway on Little Tujunga Canyon Road. Funny Man ... Hackett co-founded the Singita Animal Sanctuary back in 2003. ...
... 20 Speaker Nancy Pelosi, along with Reps. ... Early Treatment for HIV Act (ETHA) this week with ... released the following statement: "Effective drug treatments have improved ... people living with HIV/AIDS. However, many uninsured, low-income HIV-positive ...
... The expense of raising another child may be driving the ... Doctors around the United States are reporting a sharp increase ... last year, with one noting that many of his clients ... is that the trend is due both to a decreased ...
... CHICAGO, March 20 The following is ... Kloss, AHIMA Chief Executive Officer: "There is not ... as National Coordinator to lead America,s Health Information ... great promise. His selection by President Obama ...
... with cancer of the voice box (larynx) who receive ... presented at the European Society for Medical Oncology,s Symposium ... Larynx cancer is one of the most common head ... deaths reported worldwide each year. , "The risk ...
... Today Dr. Martin Gleave of the Vancouver Prostate Centre in ... prostate cancer (CRCP) during the 24th Annual Congress of the ... we look at the way kidney cancer treatment has changed ... says Dr Gleave, "Targeted therapies may become available". , ...
Cached Medicine News:Health News:Pelosi Statement on Reintroduction of the Early Treatment for HIV Act 2Health News:With the Economy Down, Vasectomy Rates Are Up 2Health News:Castrate resistant prostate cancer: New therapeutic approaches 2
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
ACMI™ Double-J Closed Tip Ureteral Stents feature patented dual durometer thermosensitive Tecoflex® construction for physician ease of placement and patient comfort....
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... for interoperative placement to stent ... construction and continent urinary diversions. ... Intended for one-time use. CAUTION: ... must not remain indwelling more ...
Medicine Products: